- Home
- SNGX vs VYNE Comparison
SNGX vs VYNE Comparison
Compare SNGX & VYNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SNGX | VYNE |
|---|---|---|
| Founded | 1987 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.4M | 12.5M |
| IPO Year | 1987 | 2018 |
Fundamental Metrics
Financial Performance| Metric | SNGX | VYNE |
|---|---|---|
| Price | $1.39 | $0.58 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 1 |
| Target Price | ★ $6.00 | N/A |
| AVG Volume (30 Days) | 195.6K | ★ 646.4K |
| Earning Date | 11-07-2025 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $524,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $16.67 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 6.29 |
| 52 Week Low | $1.09 | $0.28 |
| 52 Week High | $6.23 | $3.00 |
Technical Indicators
Market Signals| Indicator | SNGX | VYNE |
|---|---|---|
| Relative Strength Index (RSI) | 47.26 | 65.30 |
| Support Level | $1.35 | $0.56 |
| Resistance Level | $1.46 | $0.59 |
| Average True Range (ATR) | 0.08 | 0.02 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 31.25 | 75.49 |
Price Performance
Historical ComparisonAbout SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.